TGFB1 and colonic neoplasm: In addition, the TGFβ-EMT signature was applied to a cohort of 96 colon tumors [30], and the first principal component was used to assign TGFβ-EMT signature strength to each tumor, which was then used for a two-group comparison, using a two-sided t-test, between patients who had metastases at the time of tumor resection and those who did not (Figure 4D).